CompletedPhase 4

Initial Versus Delayed PDT Combination With Conbercept in PCV

China80 participantsStarted 2017-01

Plain-language summary

To compare the initial versus delayed verteporfin photodynamic therapy (PDT) in combination with conbercept in patients with symptomatic polypoidal choroidal vasculopathy (PCV).

Who can participate

Age range

40 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Either gender，age ≥ 40.
. BCVA at study entry of 34 to 79 letters (Snellen Equivalent 20/200 to 20/25).
. Naive symptomatic PCV patients.
. Presence of PCV assessed based on ICG with active polyps with or without abnormal vascular network.
. No refractive media opacity or small pupil narrow that influence the fundus examination.
. Women must be using effective contraception, be post-menopausal for at least months prior to trial entry, or surgically sterile.
. Ability to provide written informed consent and to return for all study visits.

Exclusion criteria

. Active inflammation or infection in the study eye.
. Uncontrolled intraocular pressure (\>25 mmHg) in the study eye.
. Ocular condition in the study eye which may impact vision and confound study outcomes (e.g. vitreomacular traction, epiretinal membrane with BCVA impact, ocular inflammation, retinal vascular diseases like diabetic retinopathy or diabetic macular edema).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in Best Corrected Visual Acuity (BCVA) in each group,Compare the difference between the two groups.

Timeframe: from baseline (month 0) to month 12

Trial details

NCT IDNCT02821520

SponsorThe Eye Hospital of Wenzhou Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-06

View on ClinicalTrials.gov More Polypoidal Choroidal Vasculopathy trials